Avalo Therapeutics (AVTX) Research & Development (2014 - 2026)
Avalo Therapeutics (AVTX) posted Research & Development of $14.0 million for Q1 2026, up 5.88% on a QoQ basis from $13.3 million in Q4 2025, and up 53.97% year-over-year from $9.1 million in Q1 2025.
Avalo Therapeutics (AVTX) Research & Development (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Research & Development history runs 13 years deep, the most recent figure standing at $14.0 million for Q1 2026.
- Quarterly Research & Development rose 53.97% year-over-year to $14.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.0 million (up 74.94% YoY) and the FY2025 annual result came in at $50.1 million, up 104.95% from the prior year.
- Research & Development was $14.0 million for Q1 2026 at Avalo Therapeutics, up from $13.3 million in the prior quarter.
- Across five years, Research & Development topped out at $14.1 million in Q2 2025 and bottomed at $1.2 million in Q3 2023.
- A 5-year average of $7.9 million and a median of $8.2 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 2103.22% — and 2023, when it tumbled 82.26%.
- Avalo Therapeutics' Research & Development stood at $6.2 million in 2022, then sank by 69.75% to $1.9 million in 2023, then soared by 338.3% to $8.2 million in 2024, then jumped by 62.13% to $13.3 million in 2025, then gained by 5.88% to $14.0 million in 2026.
- Business Quant data shows AVTX's Research & Development at $14.0 million in Q1 2026, $13.3 million in Q4 2025, and $13.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | 14.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.05 Mn |
| Dec 31, 2025 | 13.27 Mn |
| Sep 30, 2025 | 13.62 Mn |
| Jun 30, 2025 | 14.07 Mn |
| Mar 31, 2025 | 9.12 Mn |
| Dec 31, 2024 | 8.18 Mn |
| Sep 30, 2024 | 9.54 Mn |
| Jun 30, 2024 | 4.60 Mn |
| Mar 31, 2024 | 2.12 Mn |
| Dec 31, 2023 | 1.87 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 4.66 Mn |
| Mar 31, 2023 | 6.01 Mn |
| Dec 31, 2022 | 6.17 Mn |
| Sep 30, 2022 | 7.04 Mn |
| Jun 30, 2022 | 8.51 Mn |
| Mar 31, 2022 | 9.58 Mn |
| Dec 31, 2021 | 11.51 Mn |
| Sep 30, 2021 | 10.55 Mn |
| Jun 30, 2021 | 12.57 Mn |